| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701. |
| 掲載誌名 | 正式名：Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 略 称：Gastric Cancer ISSNコード：14363305/14363291 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 29(3),pp.611-621 |
| 著者・共著者 | Shunji Endo, Yutaka Kimura, Naotoshi Sugimoto, Ryohei Kawabata, Atsushi Takeno, Shigeyuki Tamura, Jin Matsuyama, Masato Nakamura, Hiroki Takeshita, Motohiro Imano, Atsushi Yasuda, Hironaga Satake, Shogen Boku, Masahito Kotaka, Tomohira Takeoka, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh |
| 発行年月 | 2026/05 |
| 概要 | BACKGROUND:Patients with advanced gastric cancer and para-aortic and/or bulky lymph node metastases have extremely poor prognosis after surgery alone. The OGSG1701 phase II trial evaluated the efficacy and safety of perioperative administration of capecitabine and oxaliplatin (CapeOx). Short-term results showed promising response and resection rates. Herein, we report the final survival outcomes.METHODS:This multicenter, single-arm, phase II trial enrolled patients with histologically proven, HER2-negative or unknown gastric cancer with para-aortic (no.16a2/16b1) and/or bulky lymph node metastases. Patients received three cycles of preoperative CapeOx followed by gastrectomy with D2 ± para-aortic lymphadenectomy, and five cycles of postoperative CapeOx. The primary endpoint was response rate; the key secondary endpoints included overall survival (OS) and progression-free survival (PFS).RESULTS:Thirty patients from 14 institutions were enrolled between 2018 and 2022. At a minimum follow-up of 36 months, the 3- and 5-years OS rates were 79.0% (95% confidence interval [CI], 59.0-90.0%) and 61.0% (95% CI 38.9-77.1%), respectively. Median OS was 64.9 months (95% CI 41.2-not estimable). The 3 years PFS rate was 46.7% (95% CI 28.4-63.0%), and the median PFS was 29.0 months (95% CI 9.4-not estimable). No additional treatment-related deaths occurred during the long-term follow-up.CONCLUSIONS:Perioperative CapeOx therapy resulted in encouraging long-term survival in patients with advanced gastric cancer and extensive nodal metastasis. These findings support its potential role as a perioperative strategy for biologically high-risk gastric cancer, with an acceptable safety profile. |
| DOI | 10.1007/s10120-026-01726-x |
| PMID | 41824192 |